Literature DB >> 20230402

CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials?

Cindy Lee, Barbara-Ann Guinn, Suzanne E Brooks, Deborah Richardson, Kim Orchard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20230402     DOI： 10.1111/j.1365-2141.2010.08100.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.

Authors:  Linda B Baughn; Zohar Sachs; Klara E Noble-Orcutt; Amit Mitra; Brian G Van Ness; Michael A Linden
Journal:  Leuk Lymphoma       Date:  2016-12-16

Review 2.  Worked to the bone: antibody-based conditioning as the future of transplant biology.

Authors:  James M Griffin; Fiona M Healy; Lekh N Dahal; Yngvar Floisand; John F Woolley
Journal:  J Hematol Oncol       Date:  2022-05-19       Impact factor: 23.168

Review 3.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10

4.  Association of loss of spleen visualization on whole-body diffusion-weighted imaging with prognosis and tumor burden in patients with multiple myeloma.

Authors:  Toshiki Terao; Youichi Machida; Ukihide Tateishi; Takafumi Tsushima; Kentaro Narita; Daisuke Ikeda; Ami Fukumoto; Ayumi Kuzume; Rikako Tabata; Daisuke Miura; Masami Takeuchi; Kosei Matsue
Journal:  Sci Rep       Date:  2021-12-14       Impact factor: 4.379
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.